How is the efficacy of patient selection criteria of KEYNOTE 564 for adjuvant pembrolizumab after curative surgical treatment of clear cell renal cell carcinoma with intermediate to high risk of recurrence? A real-life data analysis from single institutional experience

ERDEM S., TANTEKİN S. A., ÖZERVARLI M. F., ERGÜL R. B., PAZIR Y., HÜRDOĞAN Ö., ...More

ESMO Congress 2025, Berlin, Germany, 17 - 21 October 2025, vol.36, pp.1423, (Full Text)

• Publication Type: Conference Paper / Full Text
• Volume: 36
• City: Berlin
• Country: Germany
• Page Numbers: pp.1423
• Istanbul University Affiliated: Yes